Enclomiphene Citrate: EMA vs. FDA Regulatory Approach

What Is Enclomiphene Citrate?

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that has been used in reproductive medicine since the 1960s. Standard clomiphene (brand name Clomid) contains roughly 62% enclomiphene and 38% zuclomiphene, its cis-isomer. The two isomers behave differently. Enclomiphene acts primarily as an estrogen receptor antagonist at the hypothalamus and pituitary, blocking negative feedback and stimulating gonadotropin release 1. Zuclomiphene, by contrast, has a much longer half-life (weeks vs. hours) and mixed agonist-antagonist activity that may contribute to estrogenic side effects during prolonged use.

Repros Therapeutics isolated enclomiphene and developed it as Androxal, targeting a specific clinical gap: men with secondary hypogonadism who wanted testosterone restoration without the fertility suppression caused by exogenous testosterone. The premise was straightforward. By removing zuclomiphene, Androxal could offer the LH- and FSH-stimulating benefits of clomiphene without the prolonged estrogenic accumulation. Phase III trials (ZA-304 and ZA-305) enrolled men with secondary hypogonadism and morning testosterone levels below 300 ng/dL, testing 12.5 mg and 25 mg oral doses against topical testosterone gel and placebo 2.

The FDA's Regulatory Path: A Complete Response Letter

The FDA never approved enclomiphene citrate. Repros Therapeutics submitted its New Drug Application for Androxal and received a Complete Response Letter (CRL) in December 2015, meaning the agency identified deficiencies that prevented approval in its current form 3. The specific deficiencies cited in the CRL were not made fully public by the company, but Repros disclosed that the FDA raised concerns about data integrity at a clinical trial site and requested additional information.

This was not the first regulatory setback for Androxal. The FDA had previously issued a CRL in 2010, requesting additional Phase III data. Repros responded by conducting the ZA-304 and ZA-305 trials, which did demonstrate that enclomiphene 25 mg restored mean testosterone to the eugonadal range (average 24-hour testosterone of 416.7 ng/dL at 16 weeks vs. 232.4 ng/dL at baseline) while maintaining sperm concentrations above 20 million/mL in the majority of subjects 2. Topical testosterone gel, by contrast, suppressed sperm counts by more than 50% in a significant fraction of the comparator arm.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism stated: "We suggest against using testosterone therapy in men who are currently trying to conceive" 4. This recommendation reinforced the clinical rationale for an alternative like enclomiphene. Yet the regulatory pathway stalled. Repros merged with Veru Inc. in 2016, and the new entity did not resubmit the Androxal NDA.

A useful way to understand enclomiphene's regulatory status is through the "approval vs. access" distinction. The compound failed the approval gate but remains legally accessible through compounding, creating a situation where clinical use has outpaced regulatory endorsement.

Why the EMA Has Not Weighed In

The European Medicines Agency operates a centralized procedure for marketing authorization that requires a formal application. No company has submitted a Marketing Authorization Application (MAA) for enclomiphene citrate to the EMA 5. The European Public Assessment Report (EPAR) database contains no record of enclomiphene as a reviewed product.

This absence reflects commercial strategy more than scientific skepticism. The EMA pathway requires a sponsor willing to invest in European regulatory submissions, GMP manufacturing for the EU market, and post-authorization pharmacovigilance commitments. After the FDA's second CRL, Repros (and later Veru) redirected resources to other pipeline candidates. Without a sponsor, there is no regulatory dossier for the EMA to evaluate.

Some EU member states allow compounding under national pharmacy legislation, but this is far more restricted than U.S. 503A/503B compounding. The European Pharmacopoeia does not include a monograph for enclomiphene citrate as a distinct entity, which limits standardized compounding across European jurisdictions. Patients in Europe who seek enclomiphene typically obtain it through private prescriptions filled by specialized compounding pharmacies in countries with permissive magistral preparation laws, or through importation pathways that vary by nation.

FDA vs. EMA: Key Regulatory Differences for SERMs

The two agencies share the same evidentiary standard (well-controlled trials demonstrating safety and efficacy) but differ in procedural mechanisms. The FDA reviews drugs through either the 505(b)(1) new drug application or the 505(b)(2) pathway, which allows reference to existing literature and prior FDA findings 6. The EMA centralized procedure results in a single marketing authorization valid across all EU member states.

For clomiphene citrate, the regulatory divergence is instructive. The FDA approved clomiphene (as Clomid and Serophene) exclusively for ovulatory dysfunction in women. The approved labeling carries a specific contraindication for use in males, though off-label prescribing for male hypogonadism is common and well-documented in urology literature 1. Kim et al. reported in a systematic review that clomiphene citrate 25 to 50 mg daily raised testosterone by an average of 292 ng/dL in hypogonadal men across pooled studies, with minimal impact on semen parameters 1.

In Europe, clomiphene has comparable approved indications limited to female anovulation. Off-label male use exists but is less common due to tighter prescribing norms in many EU health systems and less direct-to-consumer awareness.

The regulatory gap matters. Without FDA or EMA approval, enclomiphene lacks a standardized label, approved dosing, mandated adverse event reporting through manufacturer pharmacovigilance programs, and inclusion in formulary drug databases used by insurance plans.

How U.S. Patients Access Enclomiphene Today

Compounding is the primary access route. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacists can compound enclomiphene citrate from bulk pharmaceutical ingredients based on a valid prescription for an individual patient. Section 503B allows outsourcing facilities to compound larger batches without individual prescriptions, subject to FDA oversight and current Good Manufacturing Practice requirements 7.

The FDA has placed enclomiphene on its Bulk Drug Substances Under Evaluation list, meaning the agency is actively reviewing whether enclomiphene meets the criteria for continued use in compounding under 503B 8. This is a critical distinction. If the FDA determines that enclomiphene does not satisfy the safety and efficacy conditions outlined in its guidance, outsourcing facilities could lose the ability to compound it at scale.

Quality variability is a documented concern with compounded medications. A 2020 FDA survey of compounded hormone products found that 34% of tested samples failed one or more quality tests, including potency, sterility, or content uniformity 9. While this figure reflects compounded hormones broadly (not enclomiphene specifically), it underscores the risk profile of any compounded medication relative to an FDA-approved product manufactured under NDA-grade GMP.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's testosterone therapy guideline, has noted: "The use of off-label and compounded agents for male hypogonadism creates a situation where patients may receive products of uncertain quality and potency, without the safety monitoring infrastructure that comes with an approved drug" 4.

Enclomiphene Citrate Safety Data

Safety data for enclomiphene comes primarily from the Androxal Phase III clinical development program. Across the ZA-304 and ZA-305 studies, enclomiphene 12.5 mg and 25 mg were generally well tolerated over 16 weeks. The most common adverse events were headache (reported in 5.3% of enclomiphene subjects vs. 3.8% placebo), upper respiratory infection, and fatigue 2. Serious adverse events were rare and not statistically different from placebo.

Long-term safety data remain limited. The longest published exposure is approximately one year from open-label extension studies. This is a notable gap. The FDA's 2015 Endocrinologic and Metabolic Drugs Advisory Committee review of testosterone products raised broad concerns about cardiovascular risk with hormonal therapies for hypogonadism, leading to a class-wide labeling change for testosterone products. Whether these cardiovascular concerns extend to SERMs like enclomiphene has not been established in large outcomes trials.

Enclomiphene's estrogen-receptor antagonism at the hypothalamic level raises theoretical concerns about bone mineral density with prolonged use, similar to those seen with tamoxifen in premenopausal women. No studies have reported significant bone density changes during enclomiphene treatment in men over 6 to 12 months, but data beyond one year are absent 10.

Hepatotoxicity has not been a signal in enclomiphene trials. This contrasts with the parent compound clomiphene, where rare cases of liver enzyme elevation have been reported during prolonged use at higher doses (100 to 150 mg/day) in women undergoing fertility treatment 1.

What a Future Approval Path Might Look Like

Any sponsor seeking FDA approval for enclomiphene would likely need to address the data integrity issues cited in the 2015 CRL, conduct or reference additional Phase III data, and potentially include a cardiovascular safety study given the FDA's heightened scrutiny of hormonal products since the 2015 advisory committee review. The 505(b)(2) pathway could reduce the burden by allowing reference to published clomiphene data and the existing Androxal clinical database, but the FDA would still require adequate evidence of enclomiphene's distinct benefit-risk profile.

The Endocrine Society has not issued a formal position statement on enclomiphene specifically. Their 2018 guideline acknowledges clomiphene as a potential option for fertility-preserving testosterone therapy in men, with the caveat that it remains off-label: "Clinicians may consider clomiphene citrate treatment in men with hypogonadism who wish to preserve fertility, recognizing that this is an off-label use" 4.

For the EMA, a new sponsor would need to file a complete MAA through the centralized procedure, including quality (CMC), nonclinical, and clinical modules. Given that no EU-based company has publicly expressed interest in developing enclomiphene, a European marketing authorization appears unlikely in the near term.

What Prescribers and Patients Should Know

The lack of regulatory approval does not mean enclomiphene is ineffective. Phase III data support its ability to raise endogenous testosterone while preserving spermatogenesis. But approval status carries practical consequences. Without an FDA-approved label, there is no standardized prescribing information, no package insert with FDA-reviewed dosing, contraindications, or drug interactions, and no manufacturer-sponsored adverse event reporting system. Prescribers relying on compounded enclomiphene should document informed consent, monitor testosterone and gonadotropin levels at 4 to 8 week intervals during initiation, and report adverse events through the FDA's MedWatch program since no manufacturer pharmacovigilance program exists for a compounded product.

Patients should verify that their compounding pharmacy holds current state licensure and, for 503B outsourcing facilities, FDA registration. Requesting a certificate of analysis for each dispensed lot is a reasonable quality-assurance step. The typical compounded dose in clinical practice is 12.5 to 25 mg orally once daily, consistent with the Phase III trial protocol, though dosing should be individualized based on serum testosterone response and clinical symptoms.